News
In Brief
News
BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39405.459074.4E (Published 22 November 2007) Cite this as: BMJ 2007;335:1064
Use of osteoarthritis drug is suspended in UK: The UK Medicines and Healthcare Products Regulatory Agency has suspended sales of the osteoarthritis drug lumiracoxib (Prexige), pending a Europe-wide review next month. The latest global safety data have shown an increase in the risk of serious liver problems with the licensed dose of 100 mg—in some cases after treatment of less than a month. Around 5000 UK patients have received the drug since it became available in 2005, and 8.5 million prescriptions have been …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.